NCT07414316

A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.

A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Subjects With Advanced Solid Tumors.

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Beijing Geekgene Technology Co., LTD · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A Single-Center, Open-Label Clinical Study to Evaluate the Safety, Preliminary Efficacy of GK01 Cell Injection in Subjects with Advanced Solid Tumors Refractory or Intolerant to Standard Therapy

Conditions

• Advanced Solid Tumors

Interventions

Type	Name	Description
DRUG	GK01 Injection	Autologous tumor-reactive T cells injection

Timeline

• Start date: 2026-02-13
• Primary completion: 2027-02-12
• Completion: 2028-02-12
• First posted: 2026-02-17
• Last updated: 2026-02-17

Locations

1 site across 1 country: China